



# Australian Technical Advisory Group on Immunisation (ATAGI)

## Summary of the 116th meeting, 15 October 2025

### Measles

- ATAGI reviewed data on measles in infants and timing of the first dose of measles-containing vaccine.
- ATAGI has not recommended any changes to the primary schedule for measles-containing vaccine.
- The [Australian Health Protection Committee statement on measles](#) highlights 4 priority areas to address measles – on-time vaccination for children, catch-up vaccination for children and adults, all relevant vaccinations for overseas travellers, and nationally consistent information for healthcare providers and the public.
- [Infants who are travelling overseas to highly endemic areas and during outbreaks, can receive their first dose of measles vaccine from 6 months of age](#) to protect them during travel. See the [Australian Immunisation Handbook](#) for more details.
- Adolescents and adults born during or since 1966 are recommended to have received 2 doses of measles-containing vaccine. This is particularly important for adults who are travelling overseas, haven't received the two documented doses or have confirmed immunity. See the [Australian Immunisation Handbook](#) for more details.

### Respiratory syncytial virus (RSV)

- ATAGI was pleased to note the positive recommendation for [RSV vaccines \(Arexvy and Abrysvo\) for older adults published by](#) the Pharmaceutical Benefits Advisory Committee (PBAC) at its July 2025 meeting and looks forward to hearing of progress for these vaccines potentially being listed on the NIP. Australia's RSV prevention program includes free RSV vaccine (Abrysvo) under the NIP for pregnant people from 28 weeks of pregnancy, and free nirsevimab (a long-acting monoclonal antibody against RSV) for eligible infants through state and territory funded programs. These immunisation products help protect newborn babies from RSV.
- [ATAGI's recommendations for RSV prevention](#) are on the Australian Immunisation Handbook website.
- ATAGI received a presentation from UNSW Sydney on an economic evaluation model that is being developed to assess the cost-effectiveness of RSV vaccination in older adults.

### Departmental updates

- ATAGI received a presentation from the department on the [draft laws to establish the Australian Centre for Disease Control](#) (CDC). If the laws are passed, the Australian CDC will start as a standalone agency on 1 January 2026.

- ATAGI received an update from the department on potential approaches to improve efficiency and reduce complexity in the way vaccines are evaluated in [Australia's health technology assessment pathway](#).

## Other ATAGI business

- ATAGI reviewed and discussed its advice to the PBAC for upcoming immunisation products.

## Resources

- ATAGI's membership, terms of reference and declaration of interest information is available on the [Department of Health, Disability and Ageing website](#).